clinical trial · NCT03574649
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
Non Small Cell Lung CancerNab-paclitaxelCisplatin5FluorouracilCyclophosphamideETBX-011ETBX-051ETBX-061GI-4000
brief summary
This is a randomized phase 2 study to compare the efficacy of neoadjuvant, consolidation, and adjuvant immunotherapy (NANT NSCLC Combination Immunotherapy; experimental arm) to standard of care (surgery and adjuvant chemotherapy; control arm) in subjects with stage II-IIIa resectable NSCLC.
started
Jun 1, 2018
primary completion
Aug 1, 2018
completion
Aug 22, 2018
last updated
Feb 21, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol